A citation-based method for searching scientific literature

Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
Times Cited: 57







List of co-cited articles
336 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
942
1


A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Michael A Nauck, John R Petrie, Giorgio Sesti, Edoardo Mannucci, Jean-Pierre Courrèges, Marie L Lindegaard, Christine B Jensen, Stephen L Atkin. Diabetes Care 2016
100
1


Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
Robert R Henry, Sunder Mudaliar, Linda Kanitra, Michael Woloschak, Raffaella Balena. J Clin Endocrinol Metab 2012
24
4



Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study.
H Hasche, G Mertes, C Bruns, R Englert, P Genthner, D Heim, P Heyen, G Mahla, C Schmidt, B Schulze-Schleppinghof,[...]. Diabetes Nutr Metab 1999
24
4


Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
A P Sykes, G L Kemp, R Dobbins, R O'Connor-Semmes, S R Almond, W O Wilkison, S Walker, L Kler. Diabetes Obes Metab 2015
18
5


Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
John B Buse, Jenny Han, Stephan Miller, Leigh MacConell, Richard Pencek, Matthew Wintle. Curr Med Res Opin 2014
4
25


Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Hirotaka Watada, Masanari Shiramoto, Shinya Ueda, Weifeng Tang, Michiko Asano, Fredrik Thorén, Hyosung Kim, Toshitaka Yajima, David W Boulton, Eiichi Araki. Diabetes Obes Metab 2019
11
9

Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience.
David A Henry, Ian H Kerridge, Suzanne R Hill, Paul M McNeill, Evan Doran, David A Newby, Kim M Henderson, Jane Maguire, Barrie J Stokes, Graham J Macdonald,[...]. Med J Aust 2005
33
3

Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control.
Jan Šoupal, Jan Škrha, Martin Fajmon, Eva Horová, Miloš Mráz, Jan Škrha, Martin Prázný. Diabetes Technol Ther 2014
59
1

NICE guidance on sotagliflozin for type 1 diabetes.
Amanda I Adler, Jessica Cronshaw, Carl Prescott, Sanjeev Patel, Eleanor Donegan, Jasdeep Hayre. Lancet Diabetes Endocrinol 2020
3
33

How should meta-regression analyses be undertaken and interpreted?
Simon G Thompson, Julian P T Higgins. Stat Med 2002
1

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
Gordon Guyatt, Andrew D Oxman, Elie A Akl, Regina Kunz, Gunn Vist, Jan Brozek, Susan Norris, Yngve Falck-Ytter, Paul Glasziou, Hans DeBeer,[...]. J Clin Epidemiol 2011
1

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
329
1

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews.
Rebecca M Turner, Jonathan Davey, Mike J Clarke, Simon G Thompson, Julian Pt Higgins. Int J Epidemiol 2012
385
1

Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis.
Esther Donga, Olaf M Dekkers, Eleonora P M Corssmit, Johannes A Romijn. Eur J Endocrinol 2015
40
2

Controlling the risk of spurious findings from meta-regression.
Julian P T Higgins, Simon G Thompson. Stat Med 2004
721
1

Sponsorship bias in clinical research.
Joel Lexchin. Int J Risk Saf Med 2012
26
3

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
126
1

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
617
1


Recommendations for assessing the risk of bias in systematic reviews of health-care interventions.
Meera Viswanathan, Carrie D Patnode, Nancy D Berkman, Eric B Bass, Stephanie Chang, Lisa Hartling, M Hassan Murad, Jonathan R Treadwell, Robert L Kane. J Clin Epidemiol 2018
50
2

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.
Ruth S Weinstock, Dongyuan Xing, David M Maahs, Aaron Michels, Michael R Rickels, Anne L Peters, Richard M Bergenstal, Breanne Harris, Stephanie N Dubose, Kellee M Miller,[...]. J Clin Endocrinol Metab 2013
193
1

Diabetic ketoacidosis with SGLT2 inhibitors.
Giovanni Musso, Francesca Saba, Maurizio Cassader, Roberto Gambino. BMJ 2020
7
14

Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study.
Christopher C Patterson, Valma Harjutsalo, Joachim Rosenbauer, Andreas Neu, Ondrej Cinek, Torild Skrivarhaug, Birgit Rami-Merhar, Gyula Soltesz, Jannet Svensson, Roger C Parslow,[...]. Diabetologia 2019
125
1

The number of subjects per variable required in linear regression analyses.
Peter C Austin, Ewout W Steyerberg. J Clin Epidemiol 2015
342
1

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.
Michael J Bradburn, Jonathan J Deeks, Jesse A Berlin, A Russell Localio. Stat Med 2007
573
1

Constraints on publication rights in industry-initiated clinical trials.
Peter C Gøtzsche, Asbjørn Hróbjartsson, Helle Krogh Johansen, Mette T Haahr, Douglas G Altman, An-Wen Chan. JAMA 2006
51
1


Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.
C P Wilkinson, Frederick L Ferris, Ronald E Klein, Paul P Lee, Carl David Agardh, Matthew Davis, Diana Dills, Anselm Kampik, R Pararajasegaram, Juan T Verdaguer. Ophthalmology 2003
1

NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Amanda I Adler, Sharlene Ting, Ross Dent, Nick Latimer. Lancet Diabetes Endocrinol 2019
6
16

Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
David J Fisher, James R Carpenter, Tim P Morris, Suzanne C Freeman, Jayne F Tierney. BMJ 2017
75
1




Effect of ketone infusions on amino acid and nitrogen metabolism in man.
R S Sherwin, R G Hendler, P Felig. J Clin Invest 1975
328
1

Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment.
Erasmia Sampani, Pantelis Sarafidis, Aikaterini Papagianni. Expert Opin Drug Saf 2020
4
25

Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.
Hyun Mi Kang, Seon Ho Ahn, Peter Choi, Yi-An Ko, Seung Hyeok Han, Frank Chinga, Ae Seo Deok Park, Jianling Tao, Kumar Sharma, James Pullman,[...]. Nat Med 2015
510
1

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Chiara Ghezzi, Donald D F Loo, Ernest M Wright. Diabetologia 2018
85
1

Effect of fatty acids on renal ammoniagenesis in in vivo and in vitro studies.
P Vinay, G Lemieux, P Cartier, M Ahmad. Am J Physiol 1976
50
2

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
127
1


Regulation of the maximum rate of renal ammoniagenesis in the acidotic dog.
M L Halperin, P Vinay, A Gougoux, C Pichette, R L Jungas. Am J Physiol 1985
77
1

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Antonios Douros, Lisa M Lix, Michael Fralick, Sophie Dell'Aniello, Baiju R Shah, Paul E Ronksley, Éric Tremblay, Nianping Hu, Silvia Alessi-Severini, Anat Fisher,[...]. Ann Intern Med 2020
23
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.